<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977453</url>
  </required_header>
  <id_info>
    <org_study_id>GII-101-P101 (MK-3475-B59)</org_study_id>
    <secondary_id>KEYNOTE-B59</secondary_id>
    <nct_id>NCT04977453</nct_id>
  </id_info>
  <brief_title>GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study to Evaluate Safety, Tolerability, PK, and Therapeutic Activity of GI-101 as a Single Agent and in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients With Advanced, Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Innovation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GI Innovation, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      therapeutic activity of GI-101 as a single agent or in combination with pembrolizumab,&#xD;
      lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/2, open-label, dose-escalation and expansion study to evaluate the safety,&#xD;
      tolerability and anti-tumor effect of GI-101 as a single agent or in combination with&#xD;
      pembrolizumab, lenvatinib or local RT over a range of advanced and/or metastatic solid&#xD;
      tumors.&#xD;
&#xD;
      This study will comprise four parts.&#xD;
&#xD;
        -  Part A: Dose-escalation and expansion cohorts of GI-101 monotherapy&#xD;
&#xD;
        -  Part B: Dose-escalation and expansion cohorts of GI-101 plus pembrolizumab&#xD;
&#xD;
        -  Part C: Dose-optimization and expansion cohorts of GI-101 plus lenvatinib&#xD;
&#xD;
        -  Part D: Dose-optimization and expansion cohorts of GI-101 plus local RT&#xD;
&#xD;
      GI-101 is a novel bi-specific Fc fusion protein containing the CD80 ectodomain as an&#xD;
      N-terminal moiety and an interleukin (IL)-2 variant as a C-terminal moiety configurated via a&#xD;
      human immunoglobulin G4 (IgG4) Fc.&#xD;
&#xD;
      Drug Information available for: Pembrolizumab (https://www.keytrudahcp.com), Lenvatinib&#xD;
      (http://www.lenvima.com)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of Dose-Limiting Toxicity (DLTs)</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on toxicities observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs)</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on toxicities observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) according to RECIST version 1.1</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on Investigator review of radiographic imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of GI-101</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on the concentration vs time profile by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of GI-101 (T1/2)</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on the concentration vs time profile by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of GI-101</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on the concentration vs time profile by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) according to RECIST version 1.1</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on Investigator review of radiographic imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective Response (DoR) according to RECIST version 1.1</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on Investigator review of radiographic imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR) according to RECIST version 1.1</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on Investigator review of radiographic imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) according to RECIST version 1.1</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on Investigator review of radiographic imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per iRECIST guidelines</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on Investigator review of radiographic imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR per iRECIST guidelines</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Based on Investigator review of radiographic imaging.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of anti-GI-101 antibody (ADA) and neutralizing antibody (Nab)</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Serum will be assessed for the presence of ADA and Nab based on the appropriate assay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points</measure>
    <time_frame>Study Day 1, assessed up to approximately 24 months</time_frame>
    <description>Peripheral immune cell subpopulation (e.g., CD4+ T cells, CD8+ T cells, regulatory T cells) will be assessed.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Urinary Bladder Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>GI-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: GI-101, multiple ascending doses&#xD;
Dose expansion:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI-101 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: GI-101, multiple ascending doses&#xD;
Dose expansion:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI-101 + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose optimization:&#xD;
Dose expansion:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI-101 + Local Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose optimization:&#xD;
Dose expansion:</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GI-101</intervention_name>
    <description>Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).</description>
    <arm_group_label>GI-101</arm_group_label>
    <arm_group_label>GI-101 + Lenvatinib</arm_group_label>
    <arm_group_label>GI-101 + Local Radiotherapy</arm_group_label>
    <arm_group_label>GI-101 + Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.</description>
    <arm_group_label>GI-101 + Pembrolizumab</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib will be administered at an approved dose orally.</description>
    <arm_group_label>GI-101 + Lenvatinib</arm_group_label>
    <other_name>Lenvima®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local Radiotherapy</intervention_name>
    <description>Patients will receive SBRT prior to the first dose of GI-101</description>
    <arm_group_label>GI-101 + Local Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory&#xD;
             guidelines) at the time of screening.&#xD;
&#xD;
          -  Has adequate organ and marrow function as defined in protocol.&#xD;
&#xD;
          -  Measurable disease as per RECIST v1.1.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other&#xD;
             prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except&#xD;
             alopecia and Grade 2 peripheral neuropathy.&#xD;
&#xD;
          -  HIV infected patients must be on anti-retroviral therapy (ART) and have a&#xD;
             well-controlled HIV infection/disease as defined in protocol.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  An active second malignancy&#xD;
&#xD;
          -  Has active or a known history of Hepatitis B or known active Hepatitis C virus&#xD;
             infection.&#xD;
&#xD;
          -  Has active tuberculosis or has a known history of active tuberculosis&#xD;
&#xD;
          -  Active or uncontrolled infections, or severe infection within 4 weeks before study&#xD;
             treatment administration.&#xD;
&#xD;
          -  History of chronic liver disease or evidence of hepatic cirrhosis, except patients&#xD;
             with liver metastasis.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.&#xD;
&#xD;
          -  Previous immunotherapies related to mode of action of GI-101.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day&#xD;
             1.&#xD;
&#xD;
          -  Administration of prior systemic anti-cancer therapy including investigational agents&#xD;
             within 4 weeks prior to treatment.&#xD;
&#xD;
          -  Radiotherapy within the last 2 weeks before start of study treatment administration,&#xD;
             with exception of limited field palliative radiotherapy (except Part D).&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of the drug products and/or excipients&#xD;
             of GI-101, pembrolizumab or lenvatinib.&#xD;
&#xD;
        Other protocol defined inclusion exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nari Yun, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GI Innovation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly.</last_name>
    <phone>+82-2-404-2003</phone>
    <email>clinical@gi-innovation.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent's Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Kyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Byoung-Yong Shim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Byoung Chul Cho, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang Joon Shin, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae Lyun Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GI-101</keyword>
  <keyword>CD80-IgG4 Fc-IL2 variant</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

